Get the Stockscreener App
0.00
100.00%
-0.0949
AIM ImmunoTech Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has agreements with UMN Pharma Inc., Japan National Institute of Infectious Diseases, and Shionogi & Co., Ltd. for the evaluation and discussion of business relationships concerning a COVID-19 therapeutic and vaccine. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.
See More
Previous Close:
$0.0949
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$13.66M
Revenue:
$202.00K
Net Income/Loss:
$-28.96M
P/E Ratio:
0.00
EPS:
-0.6
Net Cash Flow:
$-21.85M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$0.469
AIM ImmunoTech Inc Stock (AIM) Company Profile
Name
AIM ImmunoTech Inc
Sector
Industry
Phone
352 448 7797
Address
2117 SW Highway 484, Ocala, FL
Compare AIM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.00 | 13.66M | 202.00K | -28.96M | -21.85M | -0.60 |
|
ONC
Beigene Ltd Adr
|
240.00 | 25.61B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.94 | 114.83B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.30 | 41.82M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
596.00 | 66.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
73.53 | 6.36B | 0 | -153.72M | -103.81M | -2.00 |
AIM ImmunoTech Inc Stock (AIM) Latest News
AIM ImmunoTech Reports Q1 2025 Financial Results - TipRanks
AIM ImmunoTech Announces the Presentation of Ampligen - GlobeNewswire
AIM ImmunoTech Announces the Presentation of Ampligen Oncology Data at the Recent Annual Meeting of the American Association of Immunologists - Stock Titan
AIM ImmunoTech Announces Launch of CEO Corner Platform - Investegate
AIM ImmunoTech’s Drug Ampligen to Be Tested by Japan’s National Institute of Infectious Diseases as a Potential Treatment for the New SARS Coronavirus (SARS-CoV-2) Responsible for the New Human Infectious Disease COVID-19 - ACCESS Newswire
AIM ImmunoTech’s CEO to Present at Maxim’s Infectious Disease Virtual Conference - ACCESS Newswire
AIM ImmunoTech’s Ampligen Receives Clearance from FDA for Exportation to Argentina for the Treatment of Severe Chronic Fatigue Syndrome - ACCESS Newswire
AIM ImmunoTech files to sell units, no amount given - MSN
AIM ImmunoTech, Inc. Announces Pricing of $8 Million Public Offering - ACCESS Newswire
Press Release Distribution & PR Platform - ACCESS Newswire
AIM ImmunoTech Inc. Decreases SARS-CoV-2 Infectious Viral Yields by 90% Using New In Vitro Model; Supports Further Testing of Ampligen as an Intranasal Prophylactic to Prevent COVID-19 - ACCESS Newswire
AIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024 - The Globe and Mail
AIM ImmunoTech Inc. Names Ellen Lintal as New Chief Financial Officer - marketscreener.com
AIM ImmunoTech receives NYSE American notice of delisting and appeal - MSN
AIM ImmunoTech appoints Chemerow as an Independent Director - MSN
Aim ImmunoTech CEO Thomas K Equels buys $2,583 in common stock - Investing.com Canada
AIM ImmunoTech begins trading under new ticker AIMI - Investing.com Australia
AIM ImmunoTech begins trading under new ticker AIMI By Investing.com - Investing.com India
AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market - The Manila Times
AIM ImmunoTech Changes Markets: Key Details of AIMI Ticker Switch and Special Meeting - Stock Titan
Aim Immunotech’s COO Peter Rodino III acquires shares for $43 - Investing.com Australia
Aim Immunotech’s COO Peter Rodino III acquires shares for $43 By Investing.com - Investing.com India
AIM ImmunoTech faces NYSE American delisting over low stock price By Investing.com - Investing.com South Africa
AIM ImmunoTech (AIM) Faces Delisting from NYSE American - GuruFocus
AIM ImmunoTech faces NYSE American delisting over low stock price - Investing.com
AIM ImmunoTech announces NYSE American notice of delisting and appeal - TipRanks
AIM ImmunoTech Announces NYSE American Notice of Delisting and Appeal - GlobeNewswire
NYSE American Suspends AIM ImmunoTech Trading: Company Fighting Delisting Notice - Stock Titan
NYSE American To Commence Delisting Proceedings Against Aim Immunotech Inc - marketscreener.com
NYSE American to Commence Delisting Proceedings Against AIM ImmunoTech Inc. (AIM) - Business Wire
Dow Tumbles 1,100 Points; US Economy Adds 228,000 Jobs In March - Benzinga
AIM ImmunoTech Inc. (AMEX:AIM) Q4 2024 Earnings Call Transcript - Insider Monkey
AIM ImmunoTech’s Earnings Call: Progress Amid Challenges - TipRanks
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strat - GuruFocus
AIM ImmunoTech Inc (AIM) Q4 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... By GuruFocus - Investing.com Canada
AIM ImmunoTech Announces Further Efforts to Establish Clinical Trials Assessing Ampligen as a Potential Protective and Early-Onset Treatment for the Current COVID-19 Pandemic - ACCESS Newswire
AIM Immunotech Inc Files For Mixed Shelf Offering Of Up To $100 MillionSEC Filing - MarketScreener
Why Xos Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket - Benzinga
Earnings Scheduled For March 28, 2025AIM ImmunoTech (AMEX:AIM), China Automotive Systems (NASDAQ:CAAS) - Benzinga
AIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Earnings Preview For AIM ImmunoTech - Benzinga
AIM ImmunoTech Inc. (AIM) reports earnings - Quartz
AIM Immunotech Reports Fourth Quarter And Full Year 2024 Financial Results And Provides Corporate Update - Marketscreener.com
AIM ImmunoTech Slashes Expenses While Progressing Cancer Trials With AstraZeneca - Stock Titan
AIM ImmunoTech (AIM) Upgraded to Strong Buy: What Does It Mean for the Stock? - MSN
Critical Comparison: AIM ImmunoTech (NYSE:AIM) & Windtree Therapeutics (NASDAQ:WINT) - Defense World
AIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference - GlobeNewswire
AIM ImmunoTech Inc. Shares Key Updates on Clinical Trials and Future Plans at Virtual Investor Conference - Nasdaq
AIM ImmunoTech Inc Stock (AIM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):